Atossa Therapeutics, Inc. (ATOS)

NCM – Real vaqt narxi. Valyuta: USD

2.35

-0.01 (-0.42%)

Bozor ochiq: Aug 12, 2026, 3:16 PM EDT

2.39

+0.03 (1.27%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

07.08.2026

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026. "During the quarter, we executed well across the business," stated Dr. Steven Quay, M.D.

Videolar

No Data

There is no data to display

Press-relizlar

07.08.2026

Atossa Therapeutics, Inc. (ATOS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videolar

No Data

Press-relizlar

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videolar

No Data

Press-relizlar

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Search stocks

Atossa Therapeutics, Inc. (ATOS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videolar

No Data

Press-relizlar

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videolar

No Data

Press-relizlar

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update